1.Chinese expert consensus on integrated case management by a multidisciplinary team in CAR-T cell therapy for lymphoma.
Sanfang TU ; Ping LI ; Heng MEI ; Yang LIU ; Yongxian HU ; Peng LIU ; Dehui ZOU ; Ting NIU ; Kailin XU ; Li WANG ; Jianmin YANG ; Mingfeng ZHAO ; Xiaojun HUANG ; Jianxiang WANG ; Yu HU ; Weili ZHAO ; Depei WU ; Jun MA ; Wenbin QIAN ; Weidong HAN ; Yuhua LI ; Aibin LIANG
Chinese Medical Journal 2025;138(16):1894-1896
2.Temporal trend in mortality due to congenital heart disease in China from 2008 to 2021.
Youping TIAN ; Xiaojing HU ; Qing GU ; Miao YANG ; Pin JIA ; Xiaojing MA ; Xiaoling GE ; Quming ZHAO ; Fang LIU ; Ming YE ; Weili YAN ; Guoying HUANG
Chinese Medical Journal 2025;138(6):693-701
BACKGROUND:
Congenital heart disease (CHD) is a leading cause of birth defect-related mortality. However, more recent CHD mortality data for China are lacking. Additionally, limited studies have evaluated sex, rural-urban, and region-specific disparities of CHD mortality in China.
METHODS:
We designed a population-based study using data from the Dataset of National Mortality Surveillance in China between 2008 and 2021. We calculated age-adjusted CHD mortality using the sixth census data of China in 2010 as the standard population. We assessed the temporal trends in CHD mortality by age, sex, area, and region from 2008 to 2021 using the joinpoint regression model.
RESULTS:
From 2008 to 2021, 33,534 deaths were attributed to CHD. The period witnessed a two-fold decrease in the age-adjusted CHD mortality from 1.61 to 0.76 per 100,000 persons (average annual percent change [AAPC] = -5.90%). Females tended to have lower age-adjusted CHD mortality than males, but with a similar decline rate from 2008 to 2021 (females: AAPC = -6.15%; males: AAPC = -5.84%). Similar AAPC values were observed among people living in urban (AAPC = -6.64%) and rural (AAPC = -6.12%) areas. Eastern regions experienced a more pronounced decrease in the age-adjusted CHD mortality (AAPC = -7.86%) than central (AAPC = -5.83%) and western regions (AAPC = -3.71%) between 2008 and 2021. Approximately half of the deaths (46.19%) due to CHD occurred during infancy. The CHD mortality rates in 2021 were lower than those in 2008 for people aged 0-39 years, with the largest decrease observed among children aged 1-4 years (AAPC = -8.26%), followed by infants (AAPC = -7.01%).
CONCLUSIONS
CHD mortality in China has dramatically decreased from 2008 to 2021. The slower decrease in CHD mortality in the central and western regions than in the eastern regions suggested that public health policymakers should pay more attention to health resources and health education for central and western regions.
Humans
;
Heart Defects, Congenital/mortality*
;
Male
;
Female
;
China/epidemiology*
;
Infant
;
Child, Preschool
;
Adult
;
Child
;
Adolescent
;
Infant, Newborn
;
Middle Aged
;
Young Adult
;
Aged
;
Rural Population
3.Severe COVID-19 and inactivated vaccine in diabetic patients with SARS-CoV-2 infection.
Yaling YANG ; Feng WEI ; Duoduo QU ; Xinyue XU ; Chenwei WU ; Lihua ZHOU ; Jia LIU ; Qin ZHU ; Chunhong WANG ; Weili YAN ; Xiaolong ZHAO
Chinese Medical Journal 2025;138(10):1257-1259
4.Clinical efficacy of arthroscopic medial patellofemoral complex reconstruction for recurrent patellar dislocation with high-grade trochlear dysplasia.
Fengyi HU ; Qingyang MENG ; Nayun CHEN ; Jianing WANG ; Zhenlong LIU ; Yong MA ; Yuping YANG ; Xi GONG ; Cheng WANG ; Ping LIU ; Weili SHI
Journal of Peking University(Health Sciences) 2025;57(5):947-955
OBJECTIVE:
To investigate the midterm clinical efficacy of medial patellofemoral complex (MPFC) reconstruction for recurrent patellar dislocation with high-grade trochlear dysplasia.
METHODS:
A retrospective analysis was carried out among adult patients who underwent arthroscopically assisted MPFC reconstruction between January 2014 and December 2020. Dejour classification was evaluated to grade trochlear dysplasia; tibial tubercle-trochlear groove (TT-TG) distance and Insall-Salvati index were measured. Preoperative and postoperative patient-reported outcome measures (PROMs) were compared, including International Knee Documentation Committee (IKDC) score, Kujala score, Lysholm score and Tegner score. Information regarding returning-to-sport rate, re-instability events and complications was collected. Patellar tilt (PT), lateral patellar displacement (LPD) and bisect offset (BSO) ratio were measured based on axial computed tomography before and after surgery to assess the patellofemoral congruence.
RESULTS:
A total of 46 MPFC reconstructions in 43 patients were enrolled, including 16 male and 27 female. Mean age at surgery was (22.2±7.6) years (range: 14-44 years). Mean follow-up was (49.9±22.6) months (range: 18-102 months). The percentages of Dejour B, C and D dysplasia were 37.0% (17/46), 43.5% (20/46), and 19.6% (9/46), respectively. Mean Insall-Salvati index was 1.2±0.2 (range: 0.85-1.44), and mean TT-TG distance was (19.6±3.5) mm (range: 10.6-28.7 mm). At latest follow-up, there were significant improvements in all PROMs (P < 0.001): IKDC score, from 56.3±15.1 to 86.2±8.1; Kujala score, from 58.9±15.6 to 92.6±5.4; Lysholm score, from 63.7±15.0 to 94.0±5.7; Tegner score, from 3.1±1.4 to 4.7±1.4, and there were no significant differences in the improvements of the scores between the patients with Dejour B, C and D dysplasia. Overall, ninety percent of the patients returned to their preoperative sports level. One patient reported a postoperative subluxation, while no cases of infection, limited range of motion or patella fracture were observed. PT, LPD and BSO ratio were all significant altered (P < 0.001) after MPFC reconstruction.
CONCLUSION
Arthroscopically assisted MPFC reconstruction yielded satisfactory midterm clinical results for recurrent patellar dislocation with high-grade trochlear dysplasia. No significant differences of improvements in knee function were observed among the three types of high-grade trochlear dysplasia.
Humans
;
Patellar Dislocation/surgery*
;
Male
;
Female
;
Adult
;
Arthroscopy/methods*
;
Retrospective Studies
;
Adolescent
;
Young Adult
;
Patellofemoral Joint/surgery*
;
Recurrence
;
Plastic Surgery Procedures/methods*
;
Patella/surgery*
;
Treatment Outcome
5.Combination of proteome and transcriptome analysis to predict survival and immunotherapy response in patients with head and neck squamous cell carcinoma.
Yang HE ; Hui YANG ; Weili KONG
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2025;39(11):1086-1093
Objective:Proteins are closely associated with the development, progression, and immunotherapy of head and neck squamous cell carcinoma(HNSCC). However, few clinical models utilize proteomics to predict prognosis and immunotherapy efficacy. In this study, we developed a protein prognostic model(PPM) to stratify survival outcomes and differential immunotherapy responses in HNSCC patients. Methods:Based on proteomic profiling, we constructed a PPM comprising 11 protein markers. Patients were classified into high-and low-risk groups according to PPM scores. The prognostic value of risk scores was evaluated using Cox regression analysis, and predictive accuracy was assessed via time-dependent receiver operating characteristic(ROC) curves. Additionally, we analyzed treatment responses to PD1/CTLA4 immunotherapy in PD1-or CTLA4-positive patients across risk groups. Results:Cox regression confirmed the risk score as an independent prognostic factor(HR=1.161, 95%CI 1.112-1.213, P<0.001), with high-risk patients exhibiting significantly poorer survival than low-risk counterparts. The model demonstrated robust predictive accuracy, with 1-year and 3-year time-dependent ROC areas under the curve(AUC) of 0.713 and 0.707, respectively. In PD1/CTLA4-positive subgroups, low-risk patients showed superior immunotherapy responses compared to high-risk patients. Conclusion:The PPM can provide reliable prognostic stratification and preliminary guidance for immunotherapy in HNSCC. However, further clinical studies and basic experiments are needed for further verification.
Humans
;
Immunotherapy
;
Squamous Cell Carcinoma of Head and Neck/therapy*
;
Prognosis
;
Head and Neck Neoplasms/genetics*
;
Proteome
;
Proteomics
;
Gene Expression Profiling
;
Transcriptome
;
CTLA-4 Antigen
;
Programmed Cell Death 1 Receptor
;
Male
;
Female
;
Middle Aged
6.The Oncogenic Role of TNFRSF12A in Colorectal Cancer and Pan-Cancer Bioinformatics Analysis
Chuyue WANG ; Yingying ZHAO ; You CHEN ; Ying SHI ; Zhiying YANG ; Weili WU ; Rui MA ; Bo WANG ; Yifeng SUN ; Ping YUAN
Cancer Research and Treatment 2025;57(1):212-228
Purpose:
Cancer has become a significant major public health concern, making the discovery of new cancer markers or therapeutic targets exceptionally important. Elevated expression of tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) expression has been observed in certain types of cancer. This project aims to investigate the function of TNFRSF12A in tumors and the underlying mechanisms.
Materials and Methods:
Various websites were utilized for conducting the bioinformatics analysis. Tumor cell lines with stable knockdown or overexpression of TNFRSF12A were established for cell phenotyping experiments and subcutaneous tumorigenesis in BALB/c mice. RNA-seq was employed to investigate the mechanism of TNFRSF12A.
Results:
TNFRSF12A was upregulated in the majority of cancers and associated with a poor prognosis. Knockdown TNFRSF12A hindered the colorectal cancer progression, while overexpression facilitated malignancy both in vitro and in vivo. TNFRSF12A overexpression led to increased nuclear factor кB (NF-κB) signaling and significant upregulation of baculoviral IAP repeat containing 3 (BIRC3), a transcription target of the NF-κB member RELA, and it was experimentally confirmed to be a critical downstream factor of TNFRSF12A. Therefore, we speculated the existence of a TNFRSF12A/RELA/BIRC3 regulatory axis in colorectal cancer.
Conclusion
TNFRSF12A is upregulated in various cancer types and associated with a poor prognosis. In colorectal cancer, elevated TNFRSF12A expression promotes tumor growth, potentially through the TNFRSF12A/RELA/BIRC3 regulatory axis.
7.Risk management of catheterization room in interventional therapy of congenital heart disease in children
Lijun DAI ; Weili YANG ; Yanru CHEN
China Modern Doctor 2025;63(18):5-8
Objective To investigate the application of catheterization laboratory risk management in the interventional treatment of children with congenital heart disease(CHD),aiming to construct a comprehensive and practical risk management intervention plan to enhance treatment safety and child patient experience.Methods A total of 120 pediatric patients who underwent interventional treatment in the Pediatric Cardiovascular Department of the Interventional Center of Imaging and Nuclear Medicine,the Second Affiliated Hospital of Wenzhou Medical University from January 2021 to December 2022 were randomly divided into two groups(60 cases in each group).Child patients in control group received routine care,while child patients in observation group were subjected to a risk management strategy of the catheterization laboratory on the basis of control group,which included preoperative assessment,psychological intervention,intraoperative monitoring and prevention,stress management and postoperative care.Mental health status of the children,incidence of risk events and nursing disputes,as well as satisfaction of two groups were compared.Results Under the risk management strategy,the levels of anxiety and depression in observation group significantly decreased,with anxiety score dropping from(56.8±4.6)before treatment to(30.8±2.6)after treatment,and depression score falling from(55.8±2.5)to(31.4±1.6),demonstrating a significant improvement(P<0.01).After implementing the risk management strategy,the incidence of risk events in observation group was notably lower than that in control group(5.0%vs.15.0%),and medical disputes were also significantly reduced(3.3%vs.11.7%).The overall satisfaction rate in observation group was 95.0%,significantly higher than 78.3%in control group(P=0.0012).Conclusion A comprehensive risk management plan can effectively reduce the incidence of risk events and medical disputes in the interventional treatment of pediatric CHD,significantly improving child patient satisfaction and mental health status.This confirms the vital role of risk management strategies in optimizing the treatment process,reducing adverse events,and enhancing doctor-patient harmony,providing clinical reference of safer interventional treatment services for children with CHD.
8.Historical Evolution and Modern Research Progress of Dipsaci Radix Processing
Weili MA ; Xiaofeng JIN ; Qiaoxia SHI ; Ziming JIN ; Xia DOU ; Li YANG
Chinese Journal of Information on Traditional Chinese Medicine 2025;32(9):174-179
Dipsaci Radix is a commonly used yang tonifying medicine in clinical practice.Ancient books record that its preparation methods are diverse,mainly concentrated in the Ming and Qing dynasties,including wine soaking,wine washing,wine baking,wine stir frying,stir frying,wine mixing,and salt water stir frying.Wine roasting can promote blood circulation,dispel cold stagnation,and has been used throughout history;salt roasting has been seen in modern times,which can induce Chinese materia medica to descend and enhance liver and kidney tonifying effects;at present,it is mainly used for slicing raw materials,but there are also processed products such as wine fried products,salt fried products,stir fried slices,and charcoal slices.This article reviewed the herbal monographs,TCM ancient books,processing standards and modern literature,and combed the related elaboration of the processing history and modern processing research of Dipsaci Radix in the literature,so as to provide references for the processing mechanism,method research,clinical application and resource development and utilization of Dipsaci Radix.
9.Expert consensus on surgical treatment and rehabilitation for competitive sports athletes returning to sports after anterior cruciate ligament injury (version 2025)
Kai HUANG ; Lunhao BAI ; Qing BI ; Hong CHEN ; Jiwu CHEN ; Xuesong DAI ; Wenyong FEI ; Weili FU ; Zhizeng GAO ; Lin GUO ; Yinghui HUA ; Jingmin HUANG ; Suizhu HUANG ; Xuan HUANG ; Jian LI ; Qiang LI ; Shuzhen LI ; Yanlin LI ; Yunxia LI ; Zhong LI ; Ning LIU ; Yuqiang LIU ; Wei LU ; Hongbin LYU ; Haile PAN ; Xiaoyun PAN ; Chao QI ; Weiliang SHEN ; Luning SUN ; Jin TANG ; Zimin WANG ; Bide WANG ; Ru WANG ; Shaobai WANG ; Licheng WEI ; Weidong XU ; Yongsheng XU ; Jizhou YANG ; Liang YANG ; Rui YANG ; Hongbo YOU ; Tengbo YU ; Jiakuo YU ; Bing YUE ; Hua ZHANG ; Hui ZHANG ; Qingsong ZHANG ; Xintao ZHANG ; Jiajun ZHAO ; Lilian ZHAO ; Qichun ZHAO ; Song ZHAO ; Jiapeng ZHENG ; Jiang ZHENG ; Zhi ZHENG ; Jingbin ZHOU ; Jinzhong ZHAO
Chinese Journal of Trauma 2025;41(4):325-338
With the rapid development of competitive sports, the incidence of anterior cruciate ligament (ACL) injury is on the rise. Such injuries may shorten athletes′ career and lead to other long-term adverse consequences. Although athletes generally recover well after ACL reconstruction, many still struggle to return to their pre-injury performance levels. Advances in the understanding of ACL anatomy and injury mechanisms, along with the evolution of surgical techniques and rehabilitation methods, have provided more individualized and tailored options for athletes following ACL injuries. However, there is currently no consensus in China regarding surgical and rehabilitation strategies for competitive athletes aiming to return to sports after ACL injuries. To this end, the Sports Medicine Committee of the Chinese Research Hospital Association and the Editorial Board of the Chinese Journal of Trauma jointly formulated the Expert consensus on surgical treatment and rehabilitation for competitive sports athletes returning to sports after anterior cruciate ligament injury ( version 2025), and presented 14 recommendations covering surgical indications, preoperative rehabilitation, surgical timing, surgical strategies and postoperative rehabilitation strategies, aiming to improve the surgical treatment and rehabilitation system for ACL injuries in competitive athletes and facilitate their return to high-level sports performance after injury.
10.Advancements in artificial intelligence for the precise diagnosis and treatment of hematological malignancies
Haoxu YANG ; Jie XIONG ; Weili ZHAO
Chinese Journal of Hematology 2025;46(2):186-192
Hematological malignancy is a highly heterogeneous disease with complex biological characteristics and diverse clinical manifestations. Therefore, precise diagnosis and treatment are crucial and urgently needed. To further improve the accuracy of diagnosis and prognostication and to promote personalized therapy, artificial intelligence (AI) has been increasingly used. This study reviewed literature published in the last 5 years and summarized the application, benefits, and drawbacks of AI in the diagnosis, treatment, and prognosis of hematologic malignancies. Although AI can effectively improve the accuracy of diagnosis and therapy, low-quality data, poor interpretability of the model, and limited clinical transformation have impeded its popularization and application. In the future, the clinical application of AI in hematologic malignancy can be accelerated by establishing standards for clinical data processing, integrating multimodal information for accurate diagnosis and prognostication, and conducting systematic clinical verification of model algorithms.

Result Analysis
Print
Save
E-mail